US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Axcella
Axcella Announces Upcoming Investor Conference Presentation
October 05, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Upcoming Investor Conference Presentation
September 07, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
August 16, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Reports Second Quarter Financial Results and Provides Business Update
July 29, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
July 22, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
June 30, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
May 24, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
May 11, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125
May 11, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Reports First Quarter Financial Results and Provides Business Update
May 06, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella to Report First Quarter 2021 Financial Results on May 6, 2021
April 27, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
April 22, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
April 13, 2021
From
Axcella
Via
Business Wire
Tickers
AXLA
